Meeting Coverage:

American Academy of Ophthalmology

AAO: 2022

GA Update: Phase 3 Data for Pegcetacoplan

Show Description +

Charles C. Wykoff, MD, PhD, shares positive 24-month safety, efficacy, and functional outcomes from the DERBY and OAKS trials of pegcetacoplan for geographic atrophy.

Posted: 10/10/2022

GA Update: Phase 3 Data for Pegcetacoplan

Charles C. Wykoff, MD, PhD, shares positive 24-month safety, efficacy, and functional outcomes from the DERBY and OAKS trials of pegcetacoplan for geographic atrophy.

Posted: 10/10/2022


Please log in to leave a comment.

More From AAO: 2022 Coverage